How did Akebia Therapeutics' revenue and expenses trend in Q4 2024?

**Akebia Therapeutics Inc. (AKBA) is expected to show a rise in quarterly revenue for Q4 2024**, according to the mean estimate from four analysts. Here's a detailed analysis:

1. **Revenue Trend**: Analysts anticipate a significant increase in revenue for Akebia Therapeutics Inc. for the quarter ending March 31, 2025, with a projected rise of 37.6% to $44.883 million compared to the previous year's $32.61 million. This indicates a positive trend in revenue growth for the company.
2. **Expense and Loss Projections**: Despite the expected revenue increase, Akebia Therapeutics Inc. is still anticipated to report a loss of 4 cents per share for Q4 2024. This suggests that the company's expenses are currently exceeding its revenue, resulting in a net loss.
3. **Comparative Analysis**: Akebia Therapeutics Inc. has reported a quarterly adjusted loss of 10 cents per share for the quarter ended December 31, 2024, which is lower than the same quarter last year's breakeven earnings per share. This indicates a decline in losses over time, although the company is not yet profitable.
4. **Analyst Expectations**: The mean expectation of three analysts for the quarter ending December 31, 2024, was for a loss of 8 cents per share. This suggests a slightly better outlook than the 10 cents per share loss that the company actually reported.
5. **Challenges and Strategic Initiatives**: Akebia Therapeutics Inc. has been facing challenges in terms of revenue, as evidenced by missing revenue estimates in Q3. However, the company has been making strategic advances and has strong market engagement for its product Vafseo, despite the decline in total revenue.

In conclusion, Akebia Therapeutics Inc. is expected to show a rise in revenue for Q4 2024, but the company is still anticipated to report a loss due to higher expenses. The trend of declining losses over time is positive, but the company's focus remains on achieving profitability.